Alimera Sciences (STU:ASZ1) EBIT per Share : €-0.95 (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences EBIT per Share?

Alimera Sciences's EBIT per Share for the three months ended in Mar. 2024 was €-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.95.

During the past 3 years, the average EBIT per Share Growth Rate was 8.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was 35.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 43.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Alimera Sciences's EBIT per Share or its related term are showing as below:

STU:ASZ1' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.6 Med: 29.3 Max: 73.6
Current: 8.1

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Alimera Sciences was 73.60% per year. The lowest was -25.60% per year. And the median was 29.30% per year.

STU:ASZ1's 3-Year EBIT Growth Rate is ranked better than
50.17% of 859 companies
in the Drug Manufacturers industry
Industry Median: 7.9 vs STU:ASZ1: 8.10

Alimera Sciences's EBIT for the three months ended in Mar. 2024 was €-2.34 Mil.

Alimera Sciences EBIT per Share Historical Data

The historical data trend for Alimera Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences EBIT per Share Chart

Alimera Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.01

0.20

-1.65

-0.35

Alimera Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.44	-0.95	0.02	0.02	-0.04

Alimera Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Alimera Sciences's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.043	/	25.562
=	-0.35

Alimera Sciences's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.34	/	54.357
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.95

Alimera Sciences (STU:ASZ1) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Alimera Sciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (STU:ASZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ALIM:USA ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines